Briacell Therapeutics - 30BCTXZPreferred / convertible
13F holders, Q2 2025 (June 30)3holders
$1.05avg. 13F price*
At the end of Q2 2025, 3 institutions reported holding Briacell Therapeutics - 30 (BCTXZ) in their 13F filings. The largest holders were Sabby Management, LLC ($635K), Heights Capital Management, Inc. ($574K) and UBS Group AG ($1K).
- Company
- Briacell Therapeutics - 30
- CUSIP
- 107930117
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q2 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 4 | $1.2M |
| Exits | 0 | $0 |
Ownership 3 holders
| Sabby Management, LLC | — | New | 598,743 | $635K |
| Heights Capital Management, Inc. | — | New | 552,081 | $574K |
| UBS Group AG | — | New | 1,189 | $1K |
"% of holder's portfolio" is BCTXZ's weight in each manager's 13F, not the share of Briacell Therapeutics - 30 the manager owns.